GNLX

#3928
Genelux Corporation Common Stock
2.64 USD
+4.35%
版块: 医疗保健
基础: USD
利润货币: USD
日范围
2.64
2.64
年范围
2.25
8.54
日变化
+4.35%
每月变动
0.00%
6个月变化
-50.00%
年变化
+5.18%
前一天收盘价
2.53
开盘价
2.64
买价
卖价
最低价
2.64
High
2.64
交易量
9
展开完整图表

Financials

概览 声明 统计
每季度 年度
  • Market Capitalization 118.29 M
  • Employee 26
  • Founded 2001
  • CEO N/A
  • Website www.genelux.com
  • Headquarter Delaware, United States
  • FIGI BBG0044BNBX6
  • Industry Technology
总收入
净利润
每股基本收益（基本 EPS）
总债务
自由现金流
现金及现金等价物
市盈率
-5.07
市销率
20.26 K

Genelux Corporation

Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity. The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME.

新闻